ACUTE AND SUB-CHRONIC TOXICITY ASSESSMENT OF PYRIDOSTIGMINE BROMIDE 90 MG EXTENDED- ELEASE TABLETS IN EXPERIMENTAL ANIMALS

Các tác giả

  • Do Phong Tue Military institute of drug, medical equipment quality control and research
  • To Minh Hung Military institute of drug, medical equipment quality control and research
  • Le Quoc Hung Military institute of drug, medical equipment quality control and research
  • Nguyen Hai Duong Military institute of drug, medical equipment quality control and research
  • Nguyen Van Thinh Institute of Biomedicine and Pharmacy, Vietnam Military Medical University
  • Vu Thi Que Military institute of drug, medical equipment quality control and research

DOI:

https://doi.org/10.59459/1859-1655/JMM.402

Từ khóa:

Pyridostigmine bromide 90 mg, extended-release, toxicity

Tóm tắt

Purpose: This study aimed to assess the acute and subchronic toxicity of Pyridostigmine bromide 90 mg extended-release tablets in experimental animals.

Subjects and methods: Pyridostigmine bromide 90 mg extended-release tablets were prepared complying in-house specifications. Acute oral toxicity (LD50) was determined in white mice using the Litchfield-Wilcoxon method. Subchronic toxicity was assessed in rabbits following OECD guidelines.

Results: The acute toxicity study revealed an LD50 of 17.9 mg/kg when Pyridostigmine bromide 90 mg extended-release tablets were orally administered to mice. In the subchronic toxicity assessment, rabbits were treated with Pyridostigmine bromide tablets for 28 days. Doses of 7.2 mg/kg/day and 21.6 mg/kg/day showed no significant alterations in hematological parameters (red blood cells, hemoglobin, hematocrit, mean corpuscular volume, white blood cells, platelets), blood biochemical parameters (AST, ALT, total protein, creatinine, urea), and did not cause damage to the histopathology of the liver, spleen, and kidneys in rabbits. However, the dose of 21.6 mg/kg/day resulted in a statistically significant difference in rabbit weight gain compared to those administered a dose of 7.2 mg/kg/day and those in the control group.

Tài liệu tham khảo

Do Trung Dam (2014), Methods for Determining Drug Toxicity, Medical Publishing House, pp..102-110, 132-142.

Anonymous (2000), “Gulf War and Health, Depleted Uranium, Pyridostigmine Bromide, Sarin, and Vaccines”, Institute of Medicine (IOM), pp. 207.

Aquilonius SM, Hartvig P (1986), “Clinical pharmacokinetics of cholinesterase inhibitors”, Clin Pharmacokinet, 11: 236-249.

Bigoniya P., Singh A.K., Bigoniya D., Gopalan N (2013), “Pyridostigmine bromide and potassium iodate tablet: Subacute oral toxicity and stability”, Journal of Drug Metabolism & Toxicology, 4 (2), pp. 1-11.

Hayes A.W (1994), “Principles and methods of toxicology”, Raven Press Ltd., New York, USA.

Kluwe W.M, Page J.G, Toft J.D, Ridder W.E, Chung H (1990), “Pharmacological and toxicological evaluation of orally administered pyridostigmine in dogs”, Fundam Appl Toxicol, 14, pp. 40-53.

Morgan E.W, Zaucha G.M, Waring P.P, Le Tellier Y, Seewald J.B, et al. (1990), “Ninety-Day Subchronic Oral Toxicity Study of Pyridostigmine Bromide in Rats”, Letterman Army Institute of Research Presidio, San Francisco, CA, pp. 550.

OECD 423 (2001), OECD guideline for testing of chemicals - Acute oral toxicity - Acute toxic class method.

Science Lab.com (10/09/2005 06:14 PM), Material Safety Data Sheet

Pyridostigmine Bromide MSDS, Chemicals & Laboratory Equipment, pp. 2,4.

Tải xuống

Cách trích dẫn

Do Phong Tue, To Minh Hung, Le Quoc Hung, Nguyen Hai Duong, Nguyen Van Thinh, & Vu Thi Que. (2024). ACUTE AND SUB-CHRONIC TOXICITY ASSESSMENT OF PYRIDOSTIGMINE BROMIDE 90 MG EXTENDED- ELEASE TABLETS IN EXPERIMENTAL ANIMALS. Tạp Chí Y học Quân sự, (368), 5. https://doi.org/10.59459/1859-1655/JMM.402

Số

Chuyên mục

NGHIÊN CỨU - TRAO ĐỔI
 Ngày nhận bài      22-02-2024
 Chấp nhận đăng  23-02-2024
 Ngày xuất bản      28-02-2024

Các bài báo được đọc nhiều nhất của cùng tác giả